The evolving role of nuclear molecular imaging in cancer

Expert Opinion on Medical Diagnostics

Volumn 2, Issue 7, 2008, Pages 829-842

  Kurdziel, K A ^a   Ravizzini, G ^a   Croft, B Y ^a   Tatum, J L ^a   Choyke, P L ^a   Kobayashi, H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cancer; Drug development; FDG; FLT; Imaging; Molecular imaging; PET; SPECT; Systems biology

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE; ACETIC ACID C 11; AMMONIA N 13; CETUXIMAB; CHOLINE C 11; FLUORODEOXYGLUCOSE F 18; FLUOROPACLITAXEL F 18; IBRITUMOMAB TIUXETAN; IMATINIB; INDIUM CETUXIMAB IN 111; INDIUM TRASTUZUMAB IN 111; IRINOTECAN; METHIONINE C 11; OXALIPLATIN; PACLITAXEL; PENTETREOTIDE; PENTETREOTIDE IN 111; PEPTIDE; RADIOPHARMACEUTICAL AGENT; SODIUM IODIDE; SODIUM IODIDE I 123; SODIUM IODIDE I 125; SODIUM IODIDE I 131; TECHNETIUM SULFUR COLLOID TC 99M; TEMOZOLOMIDE C 11; TOSITUMOMAB I 131; TRACER; TRASTUZUMAB; UNINDEXED DRUG;

CANCER DIAGNOSIS; CANCER RESEARCH; CANCER RESISTANCE; CELL SPECIFICITY; CELLULAR PARAMETERS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CYTOCHEMISTRY; DIAGNOSTIC VALUE; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG MONITORING; DRUG RESPONSE; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; HUMAN; IMMUNOCYTOCHEMISTRY; IN VIVO STUDY; INTERMETHOD COMPARISON; ISOTOPE LABELING; MICROENVIRONMENT; MOLECULAR IMAGING; MONOTHERAPY; NEOPLASM; NEUROENDOCRINE TUMOR; NONHUMAN; NUCLEAR MEDICINE; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THYROID CARCINOMA; TUMOR BIOPSY; VIRTUAL REALITY;

EID: 77953429500     PISSN: 17530059     EISSN: 17530067     Source Type: Journal    
DOI: 10.1517/17530059.2.7.829     Document Type: Review

References (106)

1. Society of Nuclear Medicine, Molecular Imaging Center of Excellence. 2008. [cited 2008 Match 26]. Available from: http://interactive.snm.org/ index.cfm?PageID=6431&RPID=969
2. FDA, Innovation or stagnation? Challenge and opportunity on the critical path to new medical products. US Department of Health and Human Services; 2004
3. Kulesa PM, Kasemeier JC, Teddy JM, et al. The embryonic neural crest microenvironment as a model system to explore tumor cell reprogramming and metastatic ability. Der Biol 2007;306(1):369
4. Gatenby R, Gillies R. A microenvironmental model of cacinogenesis. Nat Rev Cancer 2008;8:56-61
5. Araujo RP, Petricoin EF, Liotta LA. Mathematical modeling of the cancer cell's control circuitry: paving the way to individualized therapeutic strategies. Curr Signal Transduct Ther 2007;2(2):145-55
6. Hood L, Perlmutter RM, The impact of systems approaches on biological problems in drug discovery. Nat Biotechnol 2004;22(10):1215-7
7. Hood L, Heath JR, Phelps ME, et al. Systems biology and new technologies enable predictive and preventative medicine. Science 2004;306(5696):640-3
8. Pampaioni F, Reynaud EG, Stelzer EHK. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 2007;8(10):839-45
9. Hargreaves RJ. The role of molecular imaging in drug discovery and development. Clin Pharmacol Ther 2008;83(2):349-53
10. Hoffmart JM, Gambhir SS. Molecular imaging: the vision and opportunity for radiology in the future. Radiology 2007;244(l):39-47
11. Miller JC, Thrall JH. Clinical molecular imaging. J Am Coll Radiol 2004;l(1 Suppl):4-23
12. Price P. The role of PET scanning in determining pharmacoselective doses in oncology drug development. Ernst Schering Res Found Workshop 2007;59:185-93
13. Lucignani G, Ottobrini L, Martelli C, et al. Molecular imaging of cell-mediated cancer immunotherapy. Trends Biotechnol 2006;24(9):410-8
14. Weber WA. Positron emission tomography as an imaging biomarker. J Clin Oncol 2006;24(20):3282-92
15. Warburg O. Origin of cancer cells. Science 1956;123(3191):309-14
16. Sokoloff L, Reivich M, Kennedy C, et al. The 14-C deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the concious and anesthetized albino rat. J Neurochem 1977;28:897-916
17. Phelps ME, Huang SC, Hoffman EJ, et al. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18) 2-fluoro-2-deoxy-d-glucose: validation of method. Ann Neurol 1979;6(5):371-88
18. Kostakoglu L, Goldsmith SJ, Leonard JP, et al. Fdg-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic hodgkin disease. Cancer 2006;107(11):2678-87
19. De Geus-Oei LF, van der Heijden HFM, Visser EP, et al. Chemotherapy response evaluation with F-18-FDG PET in patients with non-small cell lung cancer. J Nucl Med 2007;48(10):1592-8
20. Hutchings M, Mikhaeel NG, Fields PA, et al. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Ann Oncol 2005;16(7):1160-8
21. Choi H, Charnsangavej C, Faria SD, et al. Ct evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. Am J Roentgenol 2004;183(6):1619-28
22. Goerres GW, Stupp R, Barghouth G, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tamours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 2005;32(2):153-62
23. Zincirkeser S, Sevinc A, Kalender ME, et al. Early detection of response to imatinib therapy for gastrointestinal stromal tumor by using 18F-FDG-positron emission tomography and computed tomography imaging. World J Gastroenterol 2007;13(15):2261-2
24. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using recist, at least in GIST. J Clin Oncol 2007;25(13):1760-4
25. Juweid ME, Stroobants S, Hoekstra OS, et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma. J Clin Oncol 2007;25(5):571-8
26. Shankar LK, Hoffman JM, Bacharach S, et al. Consensus recommendations for the use of F-18-FDG PET as an indicator of therapeutic response in patients in national cancer institute trials. J Nucl Med 2006;47(6):1059-66
27. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [F-18]fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999;35(13):1773-82
28. Iida H, Law I, Pakkenberg B, et al. Quantitation of regional cerebral blood flow corrected for partial volume effect using o-15 water and PET. I. Theory, error analysis, and stereologic comparison. J Cereb Blood Flow Metab 2000;20(8):1237-51
29. Keyes J. SUV: standard uptake or silly useless value? J Nucl Med 1995;36:1836-9
30. Lowe V, DeLong D, Hoffman J, et al. Optimum scanning protocol for FDG-PET evaluation of pulmonary malignancy. J Nucl Med 1995;36:883-7
31. Webe W, Ziegler S, Thodtmann R, et al. Reproducibiliry of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 1999;40:17767
32. Conrad GR, Sinha P. Narrow time-window dual-point F-18-FDG PET for the diagnosis of thoracic malignancy. Nucl Med Commun 2003;24(11):1129-37
33. Lapointe D, Brasseur N, Cadorette J, et al. High-resolution PET imaging for in vivo monitoring of tumor response after photodynamic therapy in mice. J Nucl Med 1999;40(5):876-82
34. Love C, Tomas MB, Tronco GG, et al. FDG PET of infection and inflammation. Radiographics 2005;25(5):1357-68
35. Goo JM, Im JG, Do KH, et al. Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 2000;216(1):117-21
36. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4(11):1334-6
37. Matthes E, Lehmann C, Scholz D, et al. Phosphorylation, anti-hiv activity and cyto-toxicity of 3?-fluorothymidine. Biochem Biophys Res Commun 1988;153(2):825-31
38. Flexner C, van der Horst C, Jacobson MA, et al. Relationship between plasma concentrations of 3′-deoxy-3′-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials. J Infect Dis 1994;170(6):1394-403
39. Been LB, Suurmeijer AJ, Cobben DC, et al. [18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 2004;31(12):1659-72
40. Buck AK, M Bommer, S Stilgenbauer, et al. Molecular imaging of proliferation in malignant lymphoma. Cancer Res 2006;66(22):11055-61
41. Kasper B, Egerer G, Gronkowski M, et al. Functional diagnosis of residual lymphomas after radiochemotherapy with positron emission tomography comparing FDG- and FLT-PET. Leuk Lymphoma 2007;48(4):746-53
42. Herrmann K, Wieder HA, Buck AK, et al. Early response assessment using 3′-deoxy-3′-[F-18] fluorothymidine-positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 2007; 13(12):3552-8
43. Krohn KA, Mankoff DA, Muzi M, et al. True tracers: comparing FDG with glucose and FLT with thymidine. Nucl Med Biol 2005;32(7):663-71
44. Muzi M, Vesselle H, Grierson JR, et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med 2005;46(2):274-82
45. Vesselle H, Grierson J, Peterson LM, et al. F-18-fluorothymidine radiation dosimetry in human PET imaging studies. J Nucl Med 2003;44(9):1482-8
46. Alexander S, Varaha ST, John G, et al. Flt: measuring tumor cell proliferation in vivo with positron emission tomography and 3′-deoxy-3′-[F-18]fluorothymidine. Semin Nucl Med 2007; 37(6):429-39
47. Smyczek-Gargya B, Fersis N, Dittmann H, et al. Pet with [18F]fluorothymidine for imaging of primary breast cancer: a pilot study. Eur J Nucl Med Mol Imaging 2004;31(5):720-4
48. Muzi M, Spence AM, O'Sullivan F, et al. Kinetic analysis of 3′-deoxy-3′-F-18-fluorothymidine in patients with gliomas. J Nucl Med 2006;47(10):1612-21
49. Shields AF, Briston DA, Chandupatla S, et al. A simplified analysis of [F-18]3′-deoxy-3′-fluorothymidine metabolism and retention. Eur J Nucl Med Mol Imaging 2005;32(11):1269-75
50. Choi SJ, Kim JS, Kim JH, et al. [18;F]3′-deoxy-3′- fluorothymidine PET for the diagnosis and grading of brain tumors. Eur J Nucl Med Mol Imaging 2005; 32(6): 653-9.
51. Oyama N, Miller TR, Dehdashti F, et al. 11c-acetate PET imaging of prostate cancer: detection of recurrent disease at psa relapse. J Nucl Med 2003;44(4):549-55
52. Fricke E, Machtens S, Hofmann M, et al. Positron emission tomography with 11c-acetate and 18F-FDG in prostate cancer patients. Eur J Nud Med Mol Imaging 2003;30(4):607-11
53. Oyama N, Akino H, Kanamaru H, et al. 11c-acetate PET imaging of prostate cancer. J Nucl Med 2002;43(2):181-6
54. Kotzerke J, Linne C, Meinhardt M, et al. [1-c-11]acetate uptake is not increased in renal cell carcinoma. Eur J Nucl Med Mol Imaging 2007;34(6):884-8
55. Ho CL, Yu SC, Yeung DW, 11c-acetate PET imaging in hepatocellular carcinoma and other liver masses. J Nucl Med 2003;44(2):213-21
56. Shreve P, Chiao PC, Humes HD, et al. Carbon-11-acetate PET imaging in renal-disease. J Nucl Med 1995;36(9):1595-601
57. Yoshimoto M, Waki A, Yonekura Y, et al. Chatacterization of acetare metabolism in tumor cells in relation to cell proliferation: acetate metabolism in tumor cells. Nucl Med Biol 2001;28(2):117-22
58. Schoder H, Larson SM. Positron emission tomography for prostate, bladder, and renal cancer. Semin Nucl Med 2004;34(4):274-92
59. Kato T, Tsukamoto E, Kuge Y, et al. Accumulation of [c-11]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer. Eur J Nucl Med Mol Imaging 2002;29(11):1492-5
60. Donahue KP, Shah NP, Lee SL, et al. Initial staging of differentiated thyroid carcinoma: continued utility of posttherapy 1-131 whole-body scintigraphy. Radiology 2008;246(3):887-94
61. Silberstein EB. Comparison of outcomes after I-123 versus I-131 preablation imaging before radioiodine ablation in differentiated thyroid carcinoma. J Nud Med 2007;48(7):1043-6
62. Rault E, Vandenberghe S, Van Holen R, et al. Comparison of image quality of different iodine isotopes (I-123, i-124, and I-131). Cancer Biother Radiopharm 2007;22(3):423-30
63. Pentlow KS, Graham MC, Lambrecht RM, et al. Quantitative imaging of iodine-124 with PET. J Nucl Med 1996;37(9):1557-62
64. Meares CF, Goodwin DA. Linking radiometals to proteins with bifunctional chelating-agents. J Protein Chem 1984;3(2):215-28
65. Liu S, Edwards SD. Bifunctional chelators for therapeutic lanthanide radiopharmaceuticals. Bioconjug Chem 2001;12(1):7-34
66. Reubi JC, Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev 2003;24(4):389-427
67. Okarvi SM. Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med Res Rev 2004;24(3):357-97
68. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur J Nucl Med Mol Imaging 2003;30(5):781-93
69. Limouris GS, Rassidakis A, KondiPaphiti A, et al. Somatostatin receptor scintigraphy of non-neuroendocrine malignancies with In-111-pentetreotide. Anticancer Res 1997;17(3B):1593-7
70. Krenning EP, Kwekkeboom DJ, Bakker WH, et al. Somatostatin receptor scintigraphy with [In-111-dtpa-d-phe1;]- and [I-123-tyr3;]-octreotide - the Rotterdam experience with more than 1000 patients. Eur J Nucl Med 1993;20(8):716-31
71. Barone R, Walrand S, Konijnenberg M, et al. Therapy using labelled somatostarin analogues: comparison of the absorbed doses with In-111-dtpa-d-phel;-octreotide and yttrium-labelled dota-d-phe1;-tyr3;-octreotide. Nucl Med Commun 2008;29(3):283-90
72. Gabriel M, Decristoforo C, Kendler D, et al. Ga-68-dota-tyr3;-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and ct. J Nucl Med 2007;48(4):508-18
73. Jacene HA, Filice R, Kasecamp W, et al. Comparison of Y-90-ibritumomab tiuxetan and I-131-tositumomab in clinical practice. J Nucl Med 2007;48(11):1767-76
74. Davies AJ, Radioimmunotherapy for b-cell lymphoma: y-90 ibritumomab tiuxetan and I-131 tositumomab. Oncogene 2007;26(25):3614-28
75. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185(HER2/neu) monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clini Oncol 1998;16(8):2659-71
76. Menard C, Smith ICP, Somorjai RL, et al. Magnetic resonance spectroscopy of the malignant prostate gland after radiotherapy: a histopathologic study of diagnostic validity. Int. J Radiar Oncol Biol Phys 2001;50(2):317-23
77. Kim YS, Konoplev SN, Montemurro F, et al. Her-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res 2001;7(12):4008-12
78. Perik PJ, Lub-De Hooge MN, Gietema JA, et al. Indium-111-1abeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer. J Clin Oncol 2006;24(15):2276-82
79. NIH Clinical Center Available from: www.clinicaltrials.gov
80. Blend MJ, Stastny JJ, Swanson SM, et al. Labeling anti-HER2/neu monoclonal antibodies with In-111 and Y-90 using a bifunctional dtpa chelating agent. Cancer Biother Radiopharm 2003;18(3):355-63
81. Milenic DE, Garmestani K, Brady ED, et al. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res 2004;10(23):7834-41
82. Press MF, Sauter G, Bernstein L, et al. Diagnostic evaluation of her-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005;11(18):6598-607
83. Cohen S, Carpenter G, King L. Epidermal growth factor-receptor-protein kinase interactions - co-purification of receptor and epidermal growth factor-enhanced phosphorylation activity. J Biol Chem 1980;255(10):4834-42
84. Rivera F, Vega-Villegas ME, Lopez-Brea MF. Cetuximab, its clinical use and future perspectives. Anticancer Drugs 2008;19(2):99-113
85. Rocha-Lima CM, Soares HP, Raez LE, et al. Egfr targeting of solid tumors. Cancer Control 2007;14(3):295-304
86. Arteaga CL. The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia. J Clini Oncol 2001;19(18):32S-40S
87. Li SQ, Schmitz KR, Jeffrey PD, et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005;7(4):301-11
88. Mellstedt H. Monoclonal antibodies in human cancer. Drugs Today 2003;39:1-16
89. Italiano A. Targeting the epidermal growth factor receptor in colorectal cancer: advances and controversies. Oncology 2006;70(3):161-7
90. Lenz HJ, Mayer RJ, Gold PJ, et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. J Clin Oncol 2004;22(14):247S
91. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23(9):1803-10
92. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with american joint committee on cancer stage iv colon adenocarcinoma - implications for a standardized scoring system. Cancer 2001;92(5):1331-46
93. Sparreboom A, van Tellingen O, Nooijen WJ, et al. Preclinical pharmacokinetics of paclitaxel and docetaxel. AntiCancer Drugs 1998;9(1):1-17
94. Kiesewetter D, Eckelman W. Radiochemical synthesis of [18F]fluoropaclitaxel ([18F]fpac). J Labelled Cpd Radiopharm 2001;44(supplement):S903-5
95. Gottesman MM, Pastan I. Biochemistry of multidrug-resistance mediated by the multidrug transporter. Annu Rev Biochem 1993;62:385-427
96. Gangloff A, Hsueh WA, Kesner AL, et al. Estimation of paclitaxel biodistribution and uptake in human-derived xenografts in vivo with 18;F-fluoropaclitaxel. J Nucl Med 2005;46(11):1866-71
97. Kurdziel K, Kiesewetter DO, Carson RE, et al. Biodistribution, radiation dose estimates, and in vivo. pgp modulation studies of 18;F-paclitaxel in nonhuman primates. J Nucl Med 2003;44(8):1330-9
98. Jagoda E, Kiesewetter D, Shimoji K, et al. Comparision of the biodistribution of fluorinated and tritiated paclitaxel (PAC) in mdr1a(-)/1b(-) knockout vs wildtype mice. J Nucl Med 2002;43(S):277P
99. Kiesewetter DO, Jagoda EM, Kao CH, et al. Fluoro-, bromo-, and iodopaclitaxel derivatives: synthesis and biological evaluation. Nucl Med Biol 2003;30(1):11-24
100. Kurdziel KA, Kalen JD, Hirsch JI, et al. Imaging multidrug resistance with 4-[18F] fluoropaclitaxel. Nucl Med Biol 2007;34(7):823-31
101. Chen CC, Meadows B, Regis J, et al. Detection of in vivo p-glycoprotein inhibition by PSC 833 using Tc-99m sestamibi. Clin Cancer Res 1997;3(4):545-52
102. Sparreboom A, Planting AST, Jewell RC, et al. Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of mdrl p-glycoprotein. AntiCancer Drugs 1999;10(8):719-28
103. NCI Molecular Imaging Database, Available from: http://www.ncbi.nlm.nih.gov/books/bookres.fcgi/micad/home.html
104. Araujo RP, Liotta LA, Petricoin EF. Proteins, drug targets and the mechanisms they control: the simple truth about complex networks. Nar Rev Drug Discov 2007;6(11):871-80
105. Terstappen GC, Schlupen C, Raggiaschi R, et al. Target deconvolution strategies in drug discovery. Nat Rev Drug Discov 2007;6(11):891-903
106. Butcher EC, Berg EL, Kunkel EJ. Systems biology in drug discovery. Nat Biotechnol 2004;22(10):1253-9